MORGAN STANLEY PLC/PUT/ELI LILLY & CO/750/0.01/20.06.25 | Market Closed - Börse Stuttgart 03:05:07 2024-07-05 pm EDT | ||
| 0.35 EUR | -5.41% |
|
| Current month | +2.94% | ||
| 1 month | -31.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.35 | -5.41% |
| 24-07-04 | 0.37 | -5.13% |
| 24-07-03 | 0.39 | +5.41% |
| 24-07-02 | 0.37 | +5.71% |
| 24-07-01 | 0.35 | +2.94% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 03:05 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME8H0U |
| ISIN | DE000ME8H0U4 |
| Date issued | 2024-02-09 |
| Strike | 750 $ |
| Maturity | 2025-06-20 (350 Days) |
| Parity | 100 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.98 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.01 € |
| Spread % | 2.86% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
